75 related articles for article (PubMed ID: 23300367)
1. Use of subjective minimizing language at hematology and oncology conferences: A systematic review.
Abusamak AA; Abusamak M; Al-Abbadi M; Rayyan A; Oran O; Mohyuddin GR; Kelkar AH; Goodman AM; Chakraborty R; Cliff ERS; Al Hadidi S
J Cancer Policy; 2024 Mar; 39():100461. PubMed ID: 38061494
[TBL] [Abstract][Full Text] [Related]
2. The Concerning Disaggregation of Gender and Racial/Ethnicity Disparity Investigation at Recent ASCO Annual Meetings.
Gardner UG; McClelland S
Am J Clin Oncol; 2024 Feb; 47(2):88-90. PubMed ID: 37853552
[TBL] [Abstract][Full Text] [Related]
3. A simplified, 2-question grading system for evaluating abstracts in orthopedic scientific meetings: a serial randomization study.
Van der Weegen W; Van Egmond JC; Geuze RE; Gosens T; Snoeker B; Poolman RW;
Acta Orthop; 2024 Apr; 95():180-185. PubMed ID: 38629944
[TBL] [Abstract][Full Text] [Related]
4. Late-Breaking Abstracts for ECO2023.
Obes Facts; 2023; 16 Suppl 1(Suppl 1):352-416. PubMed ID: 37231833
[TBL] [Abstract][Full Text] [Related]
5. International Abstracts.
Ann Burns Fire Disasters; 2020 Mar; 33(1):85-86. PubMed ID: 32523501
[No Abstract] [Full Text] [Related]
6. International Abstracts.
Ann Burns Fire Disasters; 2019 Sep; 32(3):249-252. PubMed ID: 32313542
[No Abstract] [Full Text] [Related]
7. International Abstracts.
Ann Burns Fire Disasters; 2018 Jun; 31(2):160. PubMed ID: 30374271
[No Abstract] [Full Text] [Related]
8. Abstracts DGKCH.
Innov Surg Sci; 2024 Apr; 9(Suppl1):209-252. PubMed ID: 38605824
[No Abstract] [Full Text] [Related]
9. Abstracts DGPRÄC.
Innov Surg Sci; 2024 Apr; 9(Suppl1):12-17. PubMed ID: 38605819
[No Abstract] [Full Text] [Related]
10. Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment.
Milewska S; Niemirowicz-Laskowska K; Siemiaszko G; Nowicki P; Wilczewska AZ; Car H
Int J Nanomedicine; 2021; 16():6593-6644. PubMed ID: 34611400
[TBL] [Abstract][Full Text] [Related]
11. Publication patterns of cancer cost-effectiveness studies presented at major conferences.
Chan KK; Siu E; Mozessohn L; Cheung MC
Curr Oncol; 2013 Dec; 20(6):319-25. PubMed ID: 24311947
[TBL] [Abstract][Full Text] [Related]
12. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.
Dundar Y; Dodd S; Dickson R; Walley T; Haycox A; Williamson PR
Health Technol Assess; 2006 Feb; 10(5):iii-iv, ix-145. PubMed ID: 16487455
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines.
Djulbegovic B
Best Pract Res Clin Haematol; 2005; 18(3):455-66. PubMed ID: 15792920
[TBL] [Abstract][Full Text] [Related]
14. Improving the quality of abstract reporting for economic analyses in oncology.
Ho MY; Chan KK; Peacock S; Cheung WY
Curr Oncol; 2012 Dec; 19(6):e428-35. PubMed ID: 23300367
[TBL] [Abstract][Full Text] [Related]
15. Improving the quality of abstract reporting for phase I cancer trials.
Strevel EL; Chau NG; Pond GR; Murgo AJ; Ivy PS; Siu LL
Clin Cancer Res; 2008 Mar; 14(6):1782-7. PubMed ID: 18347180
[TBL] [Abstract][Full Text] [Related]
16. Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting.
Krzyzanowska MK; Pintilie M; Brezden-Masley C; Dent R; Tannock IF
J Clin Oncol; 2004 May; 22(10):1993-9. PubMed ID: 15143092
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
